Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

被引:632
作者
Siddiquee, Khandaker
Zhang, Shumin
Guida, Wayne C.
Blaskovich, Michelle A.
Greedy, Benjamin
Lawrence, Harshani R.
Yip, M. L. Richard
Jove, Richard
McLaughlin, Mark M.
Lawrence, Nicholas J.
Sebti, Said M.
Turkson, James
机构
[1] Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32826 USA
[2] Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA
[3] Univ S Florida, Coll Med, Translat Res Lab, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, Drug Discovery Program, Tampa, FL 33612 USA
[5] Univ S Florida, Coll Med, High Throughput Screening & Chem Core Facil, H Lee moffitt Canc Ctr, Tampa, FL 33612 USA
[6] Univ S Florida, Coll Med, Res Inst, Tampa, FL 33612 USA
[7] Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[8] Univ S Florida, Coll Med, Dept Chem & Mol Med, Tampa, FL 33612 USA
[9] City Hope Comphrens Ctr, Duarte, CA 91010 USA
关键词
D O I
10.1073/pnas.0609757104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
S31-201 (NSC 74859) is a chemical probe inhibitor of Stat3 activity, which was identified from the National Cancer Institute chemical libraries by using structure-based virtual screening with a computer model of the Stat3 SH2 domain bound to its Stat3 phosphotyrosine peptide derived from the x-ray crystal structure of the Stat3 beta homodimer. S31-201 inhibits Stat3-Stat3 complex formation and Stat3 DNA-binding and transcriptional activities. Furthermore, S31-201 inhibits growth and induces apoptosis preferentially in tumor cells that contain persistently activated Stat3. Constitutively climerized and active Stat3C and Stat3 SH2 domain rescue tumor cells from S31-201-induced apoptosis. Finally, S31-201 inhibits the expression of the Stat3-regulated genes encoding cyclin D1, BcI-xL, and survivin and inhibits the growth of human breast tumors in vivo. These findings strongly suggest that the antitumor activity of S31-201 is mediated in part through inhibition of aberrant Stat3 activation and provide the proof-of-concept for the potential clinical use of Stat3 inhibitors such as S31-201 in tumors harboring aberrant Stat3.
引用
收藏
页码:7391 / 7396
页数:6
相关论文
共 35 条
  • [1] Three-dimensional structure of the Stat3β homodimer bound to DNA
    Becker, S
    Groner, B
    Müller, CW
    [J]. NATURE, 1998, 394 (6689) : 145 - 151
  • [2] Blaskovich MA, 2003, CANCER RES, V63, P1270
  • [3] STATs in oncogenesis
    Bowman, T
    Garcia, R
    Turkson, J
    Jove, R
    [J]. ONCOGENE, 2000, 19 (21) : 2474 - 2488
  • [4] The role of STATs in transcriptional control and their impact on cellular function
    Bromberg, J
    Darnell, JE
    [J]. ONCOGENE, 2000, 19 (21) : 2468 - 2473
  • [5] Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development
    Bromberg, J
    [J]. BREAST CANCER RESEARCH, 2000, 2 (02) : 86 - 90
  • [6] Stat3 as an oncogene
    Bromberg, JF
    Wrzeszczynska, MH
    Devgan, G
    Zhao, YX
    Pestell, RG
    Albanese, C
    Darnell, JE
    [J]. CELL, 1999, 98 (03) : 295 - 303
  • [7] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115
  • [8] Validating Stat3 in cancer therapy
    Darnell, JE
    [J]. NATURE MEDICINE, 2005, 11 (06) : 595 - 596
  • [9] Transcription factors as targets for cancer therapy
    Darnell, JE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 740 - 749
  • [10] Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
    Friesner, RA
    Banks, JL
    Murphy, RB
    Halgren, TA
    Klicic, JJ
    Mainz, DT
    Repasky, MP
    Knoll, EH
    Shelley, M
    Perry, JK
    Shaw, DE
    Francis, P
    Shenkin, PS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) : 1739 - 1749